Biorithm is a medtech company specializing in remote maternal-fetal care, offering an obstetric monitoring solution called Femom to improve maternal care through advanced devices and algorithms.

AOA Dx is a NYC-based company that has raised $17M in funding to develop a detection test for ovarian cancer using their GlycoLocate™ platform, which focuses on glycolipids and tumor marker gangliosides to improve early cancer detection.